news
Eli Lilly and Company and Boehringer Ingelheim announce regulatory submission for new insulin glargine biosimilar product
8 July 2013 | By Boehringer Ingelheim
EMA accepted companies' MAA...
List view / Grid view
Boehringer Ingelheim
news
Results of new meta-analysis regarding CV events in linagliptin Phase 3 trials presented at ADA
25 June 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with an increased risk of cardiovascular events in the treatment of Type 2 Diabetes (T2D), versus a number of…
news
Application submitted to the EMA for use of Pradaxa® in treatment of DVT and PE and prevention of recurrent DVT and PE
24 June 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the submission of an application to the EMA...
news
New long-term data reinforce safety profile of Pradaxa® for stroke prevention in AF
17 June 2013 | By Boehringer Ingelheim
New long-term data from the RELY-ABLE® study...
article
Ingredients In-Depth Focus 2013
In this Ingredients In-Depth Focus: Revisiting a mutual recognition agreement approach for GMP inspections to secure the safety of the supply chain of APIs; Solid form diversity of commonly used tableting excipients and its impact...
news
Boehringer Ingelheim’s investigational all-oral interferon-free combination achieved 95% viral cure rates in genotype-1b hepatitis C patients
13 June 2013 | By Boehringer Ingelheim
Data from interferon-free SOUND-C3 study...
news
Boehringer Ingelheim’s investigational faldaprevir+ achieved viral cure in 88% of treatment-naïve hepatitis C patients in Asia
8 June 2013 | By Boehringer Ingelheim
New findings presented...
news
Boehringer Ingelheim pioneers biopharmaceuticals move to China
6 June 2013 | By Boehringer Ingelheim
Boehringer Ingelheim has signed with Zhangjiang Biotech & Pharmaceutical Base Development Company...
news
LUME-Lung 1: Nintedanib* plus chemotherapy extends the life of lung cancer patients with adenocarcinoma
3 June 2013 | By Boehringer Ingelheim
LUME-Lung 1 results represent the first advance in almost a decade...
news
Superiority of afatinib* over comparator chemotherapy for patients with EGFR mutation-positive advanced lung cancer is reinforced by second Phase III study
1 June 2013 | By Boehringer Ingelheim
Data from Boehringer Ingelheim’s LUX-Lung 6 trial...
news
New European survey highlights ischaemic stroke protection as treatment priority for patients with atrial fibrillation
28 May 2013 | By Boehringer Ingelheim
Findings from a pan-European online survey...
news
Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, “Complications Combat”
24 May 2013 | By Boehringer Ingelheim
"The aim and design of the game is simple..."
news
Wireless pill bottle wins Healthcare Innovation World Cup
22 May 2013 | By Boehringer Ingelheim
AdhereTech receives $50,000 grand prize in global diabetes innovation challenge funded by Boehringer Ingelheim...
news
Boehringer Ingelheim joins Structural Genomics Consortium – for further research into uncurable diseases
6 May 2013 | By Boehringer Ingelheim
Boehringer Ingelheim has joined the Structural Genomics Consortium (SGC)...
news
Boehringer Ingelheim consistently continues growth phase in financial year 2012
24 April 2013 | By Boehringer Ingelheim
Net sales rose by 11.5 percent to around €14.7 billion...
